Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
McKesson
Mallinckrodt
Johnson and Johnson
Express Scripts

Last Updated: August 11, 2022

Investigational Drug Information for BBI608


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for BBI608?

BBI608 is an investigational drug.

There have been 23 clinical trials for BBI608. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2016.

The most common disease conditions in clinical trials are Colorectal Neoplasms, Neoplasms, and Carcinoma. The leading clinical trial sponsors are Boston Biomedical, Inc, Sumitomo Dainippon Pharma Oncology, Inc, and Sumitomo Dainippon Pharma Co., Ltd.

There are thirty-nine US patents protecting this investigational drug and five hundred and thirty-eight international patents.

Recent Clinical Trials for BBI608
TitleSponsorPhase
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored ProtocolsBoston Biomedical, IncPhase 1
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored ProtocolsSumitomo Dainippon Pharma Oncology, IncPhase 1
Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal CancerAustralasian Gastro-Intestinal Trials GroupPhase 2

See all BBI608 clinical trials

Clinical Trial Summary for BBI608

Top disease conditions for BBI608
Top clinical trial sponsors for BBI608

See all BBI608 clinical trials

US Patents for BBI608

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BBI608 See Plans and Pricing Anticancer agent Kyoto Pharmaceutical Industries, Ltd. (Kyoto, JP) Sumitomo Dainippon Pharma Co., Ltd. (Osaka, JP) See Plans and Pricing
BBI608 See Plans and Pricing 3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof Boston Biomedical, Inc. (Cambridge, MA) See Plans and Pricing
BBI608 See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
BBI608 See Plans and Pricing Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer BOSTON BIOMEDICAL, INC. (Cambridge, MA) SUMITOMO DAINIPPON PHARMA CO., LTD. (Osaka-shi, Osaka, JP) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for BBI608

Drugname Country Document Number Estimated Expiration Related US Patent
BBI608 Australia AU2015272560 2034-06-09 See Plans and Pricing
BBI608 Canada CA2951627 2034-06-09 See Plans and Pricing
BBI608 Denmark DK3153508 2034-06-09 See Plans and Pricing
BBI608 European Patent Office EP3153508 2034-06-09 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
McKesson
Mallinckrodt
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.